| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide improved agents and methods for treatment of diseases associated with β amyloid (Aβ). <P>SOLUTION: The invention features selection of Aβ antibodies having particular activities, in particular, the ability to preferentially bind to soluble, oligomeric Aβ and/or the ability to rapidly improve cognition as determined in an appropriate animal of Aβ related cognitive deficit. Preferred agents include antibodies, e.g., humanized antibodies specific for Aβ. <P>COPYRIGHT: (C)2013,JPO&INPIT |
